Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy
Conclusion
In ‘real-life’ ACS undergoing PCI, diabetic patients have higher – although not significantly – MACE rate and no difference in bleeding events. This difference in MACE was significant among clopidogrel-treated patients, whereas when newer antiplatelet agents were used the negative impact of DM on ischemic events was eliminated.
Source: Coronary Artery Disease - Category: Cardiology Tags: Original Research Source Type: research
More News: Academia | Angioplasty | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Diabetes | Diabetes Mellitus | Endocrinology | Greece Health | Heart | Heart Attack | Ischemic Stroke | Percutaneous Coronary Intervention | Plavix | Stroke | Study